Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 May;35(5):929–937. doi: 10.1128/aac.35.5.929

In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.

M E Erwin 1, R N Jones 1, M S Barrett 1, B M Briggs 1, D M Johnson 1
PMCID: PMC245131  PMID: 1854174

Abstract

GR69153 is a C-7 catechol cephalosporin with a broad spectrum of activity against members of the family Enterobacteriaceae (MICs for 50% of strains tested [MIC50s], 0.008 to 0.5 micrograms/ml), Staphylococcus aureus (MIC50, 4 micrograms/ml), Pseudomonas aeruginosa (MIC50, 0.25 micrograms/ml), Haemophilus influenzae (MIC50, 0.03 micrograms/ml), Neisseria gonorrhoeae (MIC50, 0.03 micrograms/ml), and Acinetobacter spp. (MIC50, 2 micrograms/ml). Potent GR69153 activity was also demonstrated against Moraxella catarrhalis, pneumococci, beta-hemolytic streptococci, gram-positive anaerobes, and most species of coagulase-negative staphylococci. The activity of GR69153 was generally two- to fourfold greater than that of ceftazidime. Resistance level GR69153 MICs for 90% of strains tested (greater than or equal to 32 micrograms/ml) were found most often among Citrobacter freundii, Enterobacter spp. and Morganella morganii strains. GR69153 did not significantly inhibit enterococci, Xanthomonas maltophilia, the Bacteroides fragilis group, Corynebacterium jeikeium, or Listeria monocytogenes. GR69153 was bactericidal and was generally beta-lactamase stable, and MICs were only slightly increased by high inoculum concentrations. Activity was enhanced in an iron-deficient medium, and a modest MIC difference attributed to iron availability was noted between standard agar and broth test results. GR69153 was confirmed to be a potent, catechol-substituted cephalosporin with a spectrum slightly wider than that of ceftazidime, but it was less active than cefpirome or imipenem against some gram-positive pathogens and anaerobes.

Full text

PDF
929

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AXELROD J., TOMCHICK R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958 Sep;233(3):702–705. [PubMed] [Google Scholar]
  2. Bosley G. S., Elliott J. A., Oxtoby M. J., Facklam R. R. Susceptibility of relatively penicillin-resistant Streptococcus pneumoniae to newer cephalosporin antibiotics. Diagn Microbiol Infect Dis. 1987 May;7(1):21–27. doi: 10.1016/0732-8893(87)90065-4. [DOI] [PubMed] [Google Scholar]
  3. Bullen J. J. The significance of iron in infection. Rev Infect Dis. 1981 Nov-Dec;3(6):1127–1138. doi: 10.1093/clinids/3.6.1127. [DOI] [PubMed] [Google Scholar]
  4. Curtis N. A., Eisenstadt R. L., East S. J., Cornford R. J., Walker L. A., White A. J. Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother. 1988 Dec;32(12):1879–1886. doi: 10.1128/aac.32.12.1879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jacoby G. A., Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1990 May;34(5):858–862. doi: 10.1128/aac.34.5.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L. Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):82–83. doi: 10.1007/BF01962184. [DOI] [PubMed] [Google Scholar]
  7. Jones R. N., Barry A. L., Thornsberry C. Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks. Diagn Microbiol Infect Dis. 1983 Dec;1(4):295–311. doi: 10.1016/0732-8893(83)90005-6. [DOI] [PubMed] [Google Scholar]
  8. Jones R. N. Review of the in vitro spectrum of activity of imipenem. Am J Med. 1985 Jun 7;78(6A):22–32. doi: 10.1016/0002-9343(85)90098-1. [DOI] [PubMed] [Google Scholar]
  9. Jones R. N., Thornsberry C., Barry A. L. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984 Jun;25(6):710–718. doi: 10.1128/aac.25.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kamimura T., Matsumoto Y., Okada N., Mine Y., Nishida M., Goto S., Kuwahara S. Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1979 Nov;16(5):540–548. doi: 10.1128/aac.16.5.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mochizuki H., Yamada H., Oikawa Y., Murakami K., Ishiguro J., Kosuzume H., Aizawa N., Mochida E. Bactericidal activity of M14659 enhanced in low-iron environments. Antimicrob Agents Chemother. 1988 Nov;32(11):1648–1654. doi: 10.1128/aac.32.11.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ohi N., Aoki B., Kuroki T., Matsumoto M., Kojima K., Nehashi T. Semisynthetic beta-lactam antibiotics. III. Effect on antibacterial activity and comt-susceptibility of chlorine-introduction into the catechol nucleus of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid. J Antibiot (Tokyo) 1987 Jan;40(1):22–28. doi: 10.7164/antibiotics.40.22. [DOI] [PubMed] [Google Scholar]
  15. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Richmond M. H., Clark D. C., Wotton S. Indirect method for assessing the penetration of beta-lactamase-nonsusceptible penicillins and cephalosporins in Escherichia coli strains. Antimicrob Agents Chemother. 1976 Aug;10(2):215–218. doi: 10.1128/aac.10.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Silley P., Griffiths J. W., Monsey D., Harris A. M. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrob Agents Chemother. 1990 Sep;34(9):1806–1808. doi: 10.1128/aac.34.9.1806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Simpson C. H., Feld R. D., Jaynes P. K. Centrifugal analysis for serum iron and iron-binding capacity using the IL Multistat III Analyzer. Clin Biochem. 1982 Dec;15(6):313–314. doi: 10.1016/s0009-9120(82)96918-1. [DOI] [PubMed] [Google Scholar]
  19. Watanabe N. A., Nagasu T., Katsu K., Kitoh K. E-0702, a new cephalosporin, is incorporated into Escherichia coli cells via the tonB-dependent iron transport system. Antimicrob Agents Chemother. 1987 Apr;31(4):497–504. doi: 10.1128/aac.31.4.497. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES